Breaking News
January 19, 2018 - ‘You’re Old and You Need Tests’: What We Heard This Week
January 19, 2018 - Egg-preserving hysterectomy raises heart risks later: study
January 19, 2018 - GA-map Dysbiosis Test identifies IBS patients who respond to FODMAP diet, study shows
January 19, 2018 - Study explores mortality and health-related habits in former elite athletes and their brothers
January 19, 2018 - New biodegradable sensors could assist doctors
January 19, 2018 - Modular gene enhancers may be suitable target in treatment of blood cancer
January 18, 2018 - New precision medicine trial for metastatic pancreatic cancer
January 18, 2018 - Shire Receives FDA Breakthrough Therapy Designation for Maribavir, an Investigational Treatment for Cytomegalovirus (CMV) Infection in Transplant Patients
January 18, 2018 - Pre-Existing Patient-Valve Mismatch Trips Up ViV Implant
January 18, 2018 - Adolescents: health risks and solutions
January 18, 2018 - US woman delivers baby from embryo frozen for 24 years
January 18, 2018 - Study identifies new target for treatment of depression
January 18, 2018 - LJI study reveals key player that promotes skin inflammation in atopic dermatitis
January 18, 2018 - Study devises efficient and economical strategy to screen breast and ovarian cancer gene mutations
January 18, 2018 - Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla (AG200-15) for the Prevention of Pregnancy
January 18, 2018 - Gene Therapy for Inherited Retinal Dystrophy Gets FDA Clearance
January 18, 2018 - Researchers identify a new chemical pathway that helps the brain detect sweet, savory and bitter flavors
January 18, 2018 - IBV develops platform that helps companies to diagnose wellbeing of their workforce
January 18, 2018 - Study to test new precision medicine approach for metastatic pancreatic cancer
January 18, 2018 - World’s first vaccine relieves grass pollen allergy symptoms by at least 25%, study shows
January 18, 2018 - FDA Approves New Indication for Gilotrif (afatinib) in EGFR Mutation-Positive NSCLC
January 18, 2018 - Oncologists Dish on Top Issues for 2018
January 18, 2018 - Researchers identify new potential drug target for Huntington’s disease
January 18, 2018 - Metrohm USA welcomes employees to new headquarters in Florida
January 18, 2018 - Human waste remains main source of fecal pollution in the river Danube
January 18, 2018 - Expert discusses how to stay healthy during flu season
January 18, 2018 - New biomaterials-based system improves T-cell production
January 18, 2018 - Novel gene expression analysis technique can accurately and quickly measure RNA
January 18, 2018 - Grandparents Help Shape Kids’ Views on Aging
January 18, 2018 - Absolutely Zero Stent Thrombosis at 5 Years With Bioabsorbable MiStent
January 18, 2018 - Safe Sleep for Babies | VitalSigns
January 18, 2018 - Pfizer to launch own little white pill
January 18, 2018 - Aged garlic extract may help obese people fight against inflammation, study shows
January 18, 2018 - Sex steroid hormone fluctuations may have direct effects on eye physiology and AMD
January 18, 2018 - Patients with monoclonal gammopathy at risk of developing cancer even after 30 years
January 18, 2018 - Researchers reveal potential of multivalent antibodies for HIV prevention, treatment and cure
January 18, 2018 - Dying cancer patients receiving assisted hydration live longer
January 18, 2018 - Potential male birth control pill could be developed from arrow poison
January 18, 2018 - Research reveals cost-effectiveness of whole-population screening for breast, ovarian cancer gene mutations
January 18, 2018 - Genes involved in spinal cord repair of lamprey also present in mammals, study reveals
January 18, 2018 - Researchers unravel key molecular mechanism of autoimmune and inflammatory diseases
January 18, 2018 - The State of the Drug Discovery Nation Unveiled as New Report Provides Vital Insights for the Development of New Medicines
January 18, 2018 - Dutch Study Links Implants to Increased Breast-ALCL Risk
January 18, 2018 - Five addiction experts weigh in on future of opioid crisis. Their forecast: grim
January 18, 2018 - EXD2 enzyme facilitates protein production in mitochondria
January 18, 2018 - Kessler Foundation wins $735,000 grant for training rehabilitation researchers
January 18, 2018 - Researchers find new way to halt growth of breast cancer cells
January 18, 2018 - Cantex Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia
January 18, 2018 - Civilians Now Getting Flu-Like Illness Afflicting Troops
January 18, 2018 - Discovery brings stem cell therapy for eye disease closer to the clinic
January 18, 2018 - Guts of surfers more likely to be colonized by antibiotic-resistant bacteria, study reveals
January 18, 2018 - Bacteria linked to periodontitis may play role in onset of cancer
January 18, 2018 - Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
January 18, 2018 - Early Menarche, Menopause Tied to Higher CVD Risk
January 18, 2018 - Pioneering new technique could boost understanding of causes of heart disease
January 18, 2018 - New brain imaging techniques show how infants’ brains process ‘touch’
January 18, 2018 - GSK Receives FDA Approval for Expanded Indication for Fluarix Quadrivalent (Influenza Vaccine) for Persons 6 Months and Older
January 18, 2018 - Blood Markers Point to Maladaptive LV Remodeling
January 18, 2018 - Effect of gut bacteria on specific immune cells underlies persistent liver inflammation
January 18, 2018 - Study reveals new diabetes gene in families with rare blood sugar conditions
January 18, 2018 - Fewer Hospitals Closed After Obamacare Expanded Medicaid
January 18, 2018 - At-Home Breath Training Improves Asthma Quality of Life
January 18, 2018 - Obesity can add five weeks of asthma symptoms per year in preschoolers
January 18, 2018 - Neuronal loss is very limited in Alzheimer’s disease, shows new study
January 18, 2018 - A new strategy proposed for drug discovery
January 17, 2018 - Lactation May Lower T2D Risk in Younger Women
January 17, 2018 - New Atopic Dermatitis Yardstick provides practical guidance and management insights
January 17, 2018 - New biodegradable pressure sensor could help monitor serious health conditions
January 17, 2018 - HSS orders Sectra’s 3D pre-operative planning solution for improving patient outcomes
January 17, 2018 - Study identifies six new genes regions associated with diabetes
January 17, 2018 - Women do not receive timely diagnosis for heart disease
January 17, 2018 - AbbVie’s Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints
January 17, 2018 - Should President Trump’s Physical Include a Cognitive Screen?
January 17, 2018 - Could gene therapy someday eliminate HIV?
January 17, 2018 - Researchers identify new anti-inflammatory drug target
January 17, 2018 - Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers
January 17, 2018 - Trunk Imaging Tied to Higher Nephrectomy Risk
January 17, 2018 - Campaigners incensed at failings in Africa AIDS war
January 17, 2018 - Research opens door to development of new treatment for type 2 diabetes
January 17, 2018 - Uniqsis’ novel reactor system for continuous flow synthesis
New program targets cancers affecting the liver and bile ducts

New program targets cancers affecting the liver and bile ducts

image_pdfDownload PDFimage_print

Cancers affecting the liver and bile ducts will be the target of a new program at Perlmutter Cancer Center at NYU Langone Health to provide multidisciplinary clinical care and rapidly bring important new research to the clinic.

The new program brings together the expertise of many specialists-;hepatologists, oncologists, surgeons, interventional radiologists, radiation oncologists, researchers, nurses, and other experts-;all with a shared goal to institute a comprehensive, multidisciplinary approach for addressing liver and biliary cancer. This interdisciplinary team also works in close partnership with NYU Langone’s Transplant Institute to provide patients with this important and sometimes necessary option.

Nationally renowned surgeon and researcher, Theodore H. Welling, MD, has been recruited to Perlmutter Cancer Center to lead the new program. Dr. Welling joined NYU Langone this past July after a prominent career at the University of Michigan Health System, where he served as co-director of its multidisciplinary liver tumor program.

According to the U.S. Centers for Disease Control and prevention, approximately 22,000 men and 9,000 women are diagnosed each year with some form of liver cancer. The number of cases and death rate have steadily risen over the past decade, making it now one of the more common forms of cancer in this country and globally.

“A disease this complex needs to be approached from all angles to provide the best possible patient care,” says Welling. “The liver tumor program at Perlmutter Cancer Center will offer patients a highly personalized and efficient treatment model-;each patient has a team of experts behind them to address their particular needs.” Experts also gather at a weekly multidisciplinary liver tumor board to coordinate diagnosis and treatment strategies, which includes determining whether patients might benefit from a clinical trial.

NYU Langone Health also is eager to bring the liver tumor program to the forefront of clinical innovation and research. Dr. Welling’s own clinical and investigative work focuses on developing new advances in laparoscopic liver surgery, liver transplantation, bile duct and hepatic vascular resection and reconstruction, and the role of the immune system and cancer stem cells on liver cancer development.

“The development of this program brings together many key players in the fight against liver cancer,” says Benjamin G. Neel, MD, PhD, director of Perlmutter Cancer Center. “By synergistically bridging research and clinical care through the work of clinician-scientists, we will help improve patient outcomes for those with this often fatal disease.”

The liver tumor program will evaluate and treat patients with primary liver and biliary cancers, secondary liver cancer, which is cancer that spreads to the liver, and other liver and bile duct tumors that can be difficult to diagnose and treat. The program also plans to continually launch new clinical trials, offering patients access to the most current and available treatments. Recent and forthcoming trials will specifically enhance the immune system’s ability to attack cancer cells.

“The creation of this new program allows us to strategically attack liver and biliary cancer,” Welling says. “Our multidisciplinary, patient-centric approach, integrated with important research and advancement of clinical trial investigations, arms us with the resources and mechanisms to fight back against this terrible disease.”

Tagged with:

About author

Related Articles